New hope for tough cancers: experimental drug targets key mutation
Disease control
Not yet recruiting
This study is testing a new oral drug called BPI-572270 for people with advanced cancers that have specific RAS genetic mutations. Researchers want to find the safest and most effective dose, and see if it helps control cancers like lung, colorectal, and pancreatic cancer that ha…
Phase: PHASE1, PHASE2 • Sponsor: Betta Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Mar 25, 2026 14:07 UTC